EIO Biomedical

About

EIO Biomedical is a biotechnology company developing a medical device for the prevention of postsurgical adhesions. The device is designed to issue a sprayable adhesion barrier capable of alleviating problems associated with surgical sewing. The company's proprietary device and bioprocess can convert a single unit of blood plasma for infusion, generating a unique enzymatic combination that actively reduces the adhesion-formation process. A disposable kit is provided with the device to ensure that each patient receives a safe and sterile product. The company has recently initiated a first-in-human clinical trial of their FuseX system for the prevention of surgical adhesions on schedule EIO Biomedical is an NGT3 VC portfolio company.

Facts

Funding rounds (2)

Team (3)

News mentions (1)

1. Jun 13, 2017 — www.businesswire.com: Article